Literature DB >> 20829132

Application of one-step liquid chromatography-electrospray tandem MS/MS and collision-induced dissociation to quantification of ezetimibe and identification of its glucuronated metabolite in human serum: A pharmacokinetic study.

Gholamreza Bahrami1, Bahareh Mohammadi, Pyman Malek Khatabi, Mohammad Hosein Farzaei, Mohammad Bagher Majnooni, Saba Rahimi Bahoosh.   

Abstract

A new one-step liquid chromatography-electrospray tandem MS/MS method is described to quantify ezetimibe (EZM) a novel lipid lowering drug in human serum. Also using collision-induced dissociation (CID) of the analyte, identification and chromatographic separation of its major metabolite, ezetimibe glucuronide (EZM-G) is achieved in this study. A thawed serum aliquot of 100μL was deproteinated by addition of 500μL methanol containing omeprazole as internal standard (I.S.). Separation of the drug, its metabolite and the I.S. were achieved using acetonitrile-water (70:30, v/v) as mobile phase at flow rate of 0.5mL/min on a MZ PerfectSil target C18 column. Multiple reaction monitoring (MRM) mode of precursor-product ion transition (408.7→272.0 for EZM and 345→194.5 for the I.S.) was applied for detection and quantification of the drug while, EZM-G was chromatographically separated and identified using CID. The analytical method was linear over the concentration range of 1-32ng/mL of EZM in human serum with a limit of quantification of 1ng/mL. The coefficient variation values of both inter- and intra-day analysis were less than 8% whereas the percentage error was less than 3.7. The validated method was applied in a randomized cross-over bioequivalence study of two different EZM preparations in 24 healthy volunteers.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20829132     DOI: 10.1016/j.jchromb.2010.08.023

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Micelle-enhanced spectrofluorimetric method for determination of cholesterol-reducing drug ezetimibe in dosage forms.

Authors:  Nawal A Alarfaj; Fatma A Aly
Journal:  J Fluoresc       Date:  2011-08-23       Impact factor: 2.217

2.  Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe.

Authors:  Omar Patiño-Rodríguez; Irma Torres-Roque; Maricela Martínez-Delgado; Abraham Escobedo-Moratilla; José Pérez-Urizar
Journal:  Front Pharmacol       Date:  2014-11-27       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.